Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
about
Finasteride for benign prostatic hyperplasiaThe dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depressionAdverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic ReviewDropout in a longitudinal, cohort study of urologic disease in community men.Subjective cognitive complaints relate to white matter hyperintensities and future cognitive decline in patients with cardiovascular diseaseBenign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor SyndromeUse of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineChanges in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function.Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itChemoprevention of prostate cancer with finasteride.Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.Adverse effects of common medications on male fertility.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?The impact of drugs on male fertility: a review.Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.Finasteride-its impact on sexual function and prostate cancer.Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.Antipsychotic-like properties of 5-alpha-reductase inhibitors.Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Das Post-Finasterid-Syndrom
P2860
Q24234464-A7355E39-A395-468B-885C-ADB5B8843177Q24564068-A79F74F6-6195-46DC-BABC-511633CB689BQ28069186-73CA7948-6B5A-4DCC-976E-7F6BEDC7298AQ33266615-8FB2AAF2-C924-4583-A6DA-8CCED49DC495Q33618825-4FD262C3-81BF-4691-B1AC-D0DE1DCC6693Q34003918-330A5EF5-0A15-415B-B3E4-7C501CE2F059Q34313221-24C1D5B2-3652-466D-AB1E-33E3ADEDF67EQ34457965-5238EF1A-644B-4853-8FC0-F1BCA2B7304FQ34552026-A5A9E093-C58B-4F65-BD57-A73389828794Q34604979-D2D64EFA-DADA-4874-9356-E48B0AB67585Q35407450-F76B263B-81B6-47D0-B7D5-0E3E9066598DQ35799969-F2A2B28C-54A4-49AD-BC43-0723BC2AE4DCQ36379355-18423191-CB0B-4A25-AF68-18DA2D1CD2D4Q36458457-D80E6949-B5E3-4938-9399-B1DD45258997Q36916873-4647AA2A-C557-426C-A8B9-0CDA61CC9900Q37694089-95D152DA-2FF6-49BA-8E75-25ED0FBDD94FQ37896170-A413B6E2-1B02-4097-8CA5-CB6F169AE85EQ38239520-697540E0-D914-4DCA-96EC-7EA21BB638BBQ38534996-010D62D7-A37A-4103-8230-1BD90E1B4451Q38571198-BB056A09-64DA-4F0F-9632-92C6C6DB2E7FQ38722243-A126E4BF-A511-447B-B7BC-53BE66427371Q38814349-DBADB101-CB24-4879-B7B2-10E6AB0FCA91Q38846845-AF197CBC-8BB6-4542-B4A7-718646D6DDB8Q39681594-51484F1D-B375-41CD-9DAC-80AEB3841B87Q42675109-9B6BCABF-20C4-45E2-BB70-8739AB4DFCB8Q46691569-4C00FEED-29DC-4C65-BBD8-14ADBD81CE13Q48553280-88EBCE1D-2BA4-4B39-AD95-57096353019DQ49039304-5B2A863F-99E0-4863-B7DF-6FA45026F955Q49971559-BA79784A-44BD-4600-BFDD-FDEEC967B12FQ56700760-1053F68E-9ECE-4868-A9EA-128BA4B8C687
P2860
Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@ast
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@en
type
label
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@ast
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@en
prefLabel
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@ast
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@en
P2093
P1433
P1476
Incidence and severity of sexu ...... benign prostatic hyperplasia.
@en
P2093
Alvin M Matsumoto
Hunter Wessells
Jacob Rajfer
Jennifer Culbertson
Joanne Waldstreicher
John Bannow
John Grayhack
Johnny Roy
Lisa Tenover
Mark A Bach
P304
P356
10.1016/S0090-4295(02)02401-9
P407
P577
2003-03-01T00:00:00Z